Abiomed — Sales to Customers
Products & Services · Sales to CustomersJohnson & Johnson Abiomed — Sales to Customers remained flat by 0.0% to $748.25M in Q4 2024 compared to the prior quarter. Year-over-year, this metric grew by 14.6%, from $653.00M to $748.25M. Over 2 years (FY 2022 to FY 2024), Abiomed — Sales to Customers shows an upward trend with a 594.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market adoption and successful commercialization of heart recovery technologies, while a decrease may signal market saturation or competitive pressure.
Detailed definition
This metric represents the total revenue generated from the sale of cardiovascular medical technology products within th...
Peer comparison
Comparable to revenue metrics for specialized medical device divisions or acquired cardiovascular technology segments at peer healthcare companies.
jnj_segment_abiomed_sales_to_customersHistorical Data
| FY'22 | FY'23 | FY'24 | |
|---|---|---|---|
| Value | $62.00M | $2.61B | $2.99B |
| YoY Change | — | >999% | +14.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's abiomed — sales to customers?
- Johnson & Johnson (JNJ) reported abiomed — sales to customers of $748.25M in Q4 2024.
- How has Johnson & Johnson's abiomed — sales to customers changed year-over-year?
- Johnson & Johnson's abiomed — sales to customers increased by 14.6% year-over-year, from $653.00M to $748.25M.
- What is the long-term trend for Johnson & Johnson's abiomed — sales to customers?
- Over 2 years (2022 to 2024), Johnson & Johnson's abiomed — sales to customers has grown at a 594.8% compound annual growth rate (CAGR), from $62.00M to $2.99B.
- What does abiomed — sales to customers mean?
- The total revenue earned from selling Abiomed cardiovascular medical products to customers.